Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO MALMOREDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO MALMOREDE.
DEMULEN 1/35-28 vs LO-MALMOREDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.
None Documented
None Documented
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Terminal elimination half-life is approximately 4-6 hours; prolonged to 12-18 hours in moderate-to-severe renal impairment, requiring dose interval extension.
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
Primarily renal (75-90% unchanged); renal clearance approximates GFR, with dose adjustment needed for CrCl <30 mL/min. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive